Clinical Trial Update: Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for secukinumab in active psoriatic arthritis evaluating efficacy, structural damage inhibition, safety, and tolerability up to 2 …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Psoriatic Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2019-06-28